Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)

202332 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: Gynecologic Oncology

Volume 176, pp. S31-S32

Field-Weighted Citation Impact: 7.49